68Ga-FAPI PET/CT versus 18F-FDG PET/CT: Differentiating Metastatic Disease and Reactive Lymph Nodes in a Case of Carcinoma of Breast/Acquired Immunodeficiency Syndrome

Gopinathraj Gunasekaran; Jaykanth Amalachandran

doi:10.1055/s-0044-1787718

World Journal of Nuclear Medicine, Inhaltsverzeichnis

CC BY 4.0 · World J Nucl Med 2024; 23(03): 217-219
DOI: 10.1055/s-0044-1787718

Case Report

⁶⁸Ga-FAPI PET/CT versus ¹⁸F-FDG PET/CT: Differentiating Metastatic Disease and Reactive Lymph Nodes in a Case of Carcinoma of Breast/Acquired Immunodeficiency Syndrome

Authors

Gopinathraj Gunasekaran

¹Department of Nuclear Medicine, PET-CT and Theranostics, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India
Jaykanth Amalachandran

¹Department of Nuclear Medicine, PET-CT and Theranostics, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India

Abstract

Gallium-68 (⁶⁸Ga)-fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET) images the cancer-associated fibroblast that forms a vital component of the tumor microenvironment. It is known that ⁶⁸Ga-FAPI PET can aid in differentiating reactive lymph nodes from metastatic lymph nodes. ¹⁸F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) is still the most commonly used PET radiopharmaceutical in the evaluation of a wide range of malignancies including breast carcinoma. Reactive lymph nodes may also show FDG uptake which can hinder optimal assessment for metastatic involvement. We report an interesting case of invasive ductal carcinoma of the right breast with associated World Health Organization clinical stage I acquired immunodeficiency syndrome for which ¹⁸F-FDG PET/CT and ⁶⁸Ga-FAPI PET/CT were done.

Keywords

⁶⁸Ga-FAPI - reactive node - metastatic node - breast carcinoma - positron emission tomography - PET - acquired immunodeficiency syndrome

Volltext

Referenzen

References
1 Shang Q, Zhao L, Pang Y, Meng T, Chen H. Differentiation of reactive lymph nodes and tumor metastatic lymph nodes with 68Ga-FAPI PET/CT in a patient with squamous cell lung cancer. Clin Nucl Med 2022; 47 (05) 458-461
2 Shang Q, Zhao L, Pang Y, Yu Y, Chen H. 68Ga-FAPI PET/CT distinguishes the reactive lymph nodes from tumor metastatic lymph nodes in a patient with nasopharyngeal carcinoma. Clin Nucl Med 2022; 47 (04) 367-368
3 Shou Y, Xue Q, Yuan J, Zhao J. ⁶⁸Ga-FAPI-04 PET/MR is helpful in differential diagnosis of pancreatitis from pancreatic malignancy compared to ¹⁸F-FDG PET/CT: a case report. Eur J Hybrid Imaging 2021; 5 (01) 12
4 Alçın G, Arslan E, Aksoy T. et al. 68 Ga-FAPI-04 PET/CT in selected breast cancer patients with low FDG affinity : a head-to-head comparative study. Clin Nucl Med 2023; 48 (09) e420-e430
5 Backhaus P, Burg MC, Roll W. et al. Simultaneous FAPI PET/MRI targeting the fibroblast-activation protein for breast cancer. Radiology 2022; 302 (01) 39-47
6 Taralli S, Lorusso M, Perrone E, Perotti G, Zagaria L, Calcagni ML. PET/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application-a literature review. Cancers (Basel) 2023; 15 (03) 908
7 Treglia G, Albano D. FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?. Eur J Nucl Med Mol Imaging 2023; 50 (07) 1848-1850
8 Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001; 22 (04) 199-204